EFFICACY OF AN SIV VACCINE PREPARED WITH DIFFERENT ADJUVANTS

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目及 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 用由HIV蛋白、gp 120和nef/达特组成的疫苗和SIV nef蛋白与各种专有佐剂一起沿着给药对动物进行免疫。 三次免疫后，1999年用SHIV89.6P静脉内攻击动物。 该实验于2001年由NIAID转移到WaNPRC的SVEU。 SVEU的支持将持续到今年。 存活的动物是长期不进展者，他们控制病毒复制，保持非常低或检测不到的病毒水平。 根据家庭实验室或SVEU项目官员的要求，从他们身上采集样本，以监测疫苗和攻毒引起的免疫应答的持续性，并根据需要进行健康监测。 此外，正在收集这些动物的血液，以验证新的细胞内染色试验，用于评估针对该项目以及SVEU合同支持的其他项目研究的疫苗开发的细胞免疫。 在本报告期结束前，为了更好地了解疫苗控制病毒的机制，我们计划通过使用人源化小鼠单克隆抗CD 8抗体cM-T807治疗暂时消耗体内CD 8+细胞，检查CD 8+细胞在这些动物中控制病毒的作用。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The animals were immunized with a vaccine composed of HIV proteins, gp120 and nef/tat, and SIV nef protein administered along with various proprietary adjuvants. After three immunizations, the animals were challenged intravenously with SHIV89.6P in 1999. This experiment was transferred to the SVEU at the WaNPRC by NIAID in 2001. SVEU support continues through the current year. The surviving animals are long-term nonprogressors who are controlling virus replication, maintaining very low or undetectable virus levels. Samples are collected from them as requested by the home laboratory or the SVEU project officer to monitor the persistence of immune responses elicited by the vaccine and challenge and as needed for health monitoring. Additionally, blood from these animals is being collected to validate new intracellular staining assays to be used to evaluate cellular immunity developed in response to vaccines being studied on this as well as other projects supported by the SVEU contract. Before the end of this reporting period, in an effort to better understand the mechanisms of virus control by vaccines, we plan to examine the role of CD8+ cells in controlling virus in these animals by temporarily depleting CD8+ cells in vivo by treatment with the humanized mouse monoclonal anti-CD8 antibody, cM-T807.